Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
ADMA Biologics Inc(ADMA)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ADMA
10/23/2026: ADMA (3-star) is a STRONG-BUY. BUY for 18 days. Simulated Profits (6.48%). Updated daily EoD!
ADMA Biologics is a growing biotechnology firm that specializes in the production of plasma-derived therapies for immune disorders. Its primary strength lies in its vertical integration, controlling both the collection of plasma and the manufacturing of products like Asceniv and Bivigam. This strategy has allowed the company to improve operational efficiency and achieve revenue growth. However, it faces significant competitive risks from much larger, established global manufacturers with greater financial resources. The stock may be suitable for growth-focused investors, provided they can withstand the volatility inherent in the biotechnology sector. Key developments to monitor include plasma collection growth and market share expansion for its specialty immune therapies.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company is in a high-growth phase as it scales revenue and achieves operational efficiency. |
| Momentum investor | Mixed fit | Momentum fit is conditional on positive price trends and sustained revenue growth signals. |
| Value investor | Weak fit | The stock is often priced based on future growth prospects rather than current deep-value metrics. |
| Dividend investor | Weak fit | ADMA does not pay dividends, making it unsuitable for income-focused portfolios. |
| Low-risk investor | Weak fit | The biotechnology sector and small-cap nature of the stock entail high price volatility and operational risks. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech stocks are prone to rapid price movements based on clinical or market news. |
| Valuation risk | Medium / high | Growth expectations are already priced into the stock, leaving little room for error. |
| Competition risk (Global plasma manufacturers) | High | Direct competition from firms like CSL and Takeda puts pressure on pricing and market share. |
| Business quality | Medium | While operations are improving, the firm is still maturing compared to established industry giants. |
| Dividend income | Low / none | No dividend is paid, providing no income hedge against volatility. |
| Execution risk | Medium / high | The company must consistently execute on production and collection targets to maintain growth. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit 141.24% | Avg. Invested days 42 | Today’s Advisory Strong Buy |
Upturn Advisory Rating  | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/23/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.39B USD | Price to earnings Ratio 15.26 | 1Y Target Price 17 |
Price to earnings Ratio 15.26 | 1Y Target Price 17 | ||
Volume (30-day avg) 3.2M shares | Beta 0.69 | 52 Weeks Range 7.21 - 20.46 | Updated Date 10/23/2026 |
52 Weeks Range 7.21 - 20.46 | Updated Date 10/23/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.7 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Specialty Plasma Products | Sales of Asceniv, Bivigam, and Nabi-HB to hospitals and pharmacies. | The company makes money by selling immune-boosting medicine derived from donated human plasma. |
| Plasma Collection | Operational revenue from FDA-licensed plasma centers. | They own centers that collect the raw plasma needed to manufacture their own products. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE 15.26 | Forward PE 9.01 | Enterprise Value 2.06B | Price to Sales(TTM) 4.67 |
Enterprise Value 2.06B | Price to Sales(TTM) 4.67 | ||
Enterprise Value to Revenue 4.03 | Enterprise Value to EBITDA 8.86 | Shares Outstanding 223.98M | Shares Floating 219.66M |
Shares Outstanding 223.98M | Shares Floating 219.66M | ||
Percent Insiders 1.97 | Percent Institutions 92.54 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.